Novartis NVS
-
Pfizer: Don't Overlook This $22 Gem
… analytical overview of pharmaceuticals companies in the U.S. Using the example of Pfizer along with Merck ( MRK ) , Novartis AG ( NVS ) and Sanofi ( SNY ) , will be enough to prove to you why this industry holds the key to a healthy portfolio. Brief …
-
Novartis : The Market Is Wrong About This Pharma Stock
… the opportunity outweighs the risk at this point. Novartis (NYSE: NVS ) remains an excellent investment, offering both ..... have to endure more punishment in the near-term as Novartis works through its issues (and Complete Story »
-
The Achilles Heel of the US Economy
Novartis has one of the best drug pipelines in the industry.
-
VHT Vanguard Health Care ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… owns only companies domiciled in the United States, which means that it doesn't invest in foreign behemoths such as Novartis NVS , Roche, and Sanofi-Aventis SNY. That said, many of the companies in VHT operate businesses spanning the globe …
-
XLV Health Care Select Sector SPDR ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… criteria eliminate foreign health-care companies, the index excludes international health-care behemoths such as Novartis NVS , GlaxoSmithKline GSK, Roche, and Sanofi-Aventis. That said, we'd note that most of the firms included here …
-
Perrigo ([[PRGO]] -0.2%) has received final FDA approval for its abbreviated new drug application for Lansoprazole capsules for the treatment of frequent heartburn. Shipments of the product to ...
… capsules for the treatment of frequent heartburn. Shipments of the product to customers have already begun. This new product for the U.S. store brand market is the equivalent to Novartis ' ( NVS ) Prevacid 24 hour capsules. Post your comment!
-
New Morningstar Analyst Report - Hospira, Inc.
… regulatory hurdles for biosimilars will minimize competitor entry. Hospira, Teva TEVA, and Sandoz (a subsidiary of Novartis NVS ) lead the market for biosimilars in Europe, and Hospira hopes to be a leader in the nascent U.S. biosimilars market …
-
New Morningstar Analyst Report - Mylan, Inc.
… largest generic pharmaceutical manufacturer, Mylan is a significant competitor. Teva TEVA, Sandoz (a subsidiary of Novartis NVS ), Mylan, and Watson WPI control an estimated 50% of the world generic market and are able to achieve greater economies …
-
Eli Lilly Could Sink On Drug Collusion In India
… with India's drug regulators. Eli Lilly, along with other Big Pharma names such as GlaxoSmithKline ( GSK ) and Novartis ( NVS ) , has been colluding with Indian drug regulators to speed up approval procedures and put drugs on the Indian market …
-
UPDATE 3-FDA says unsure if Novartis MS pill caused deaths
WASHINGTON, May 14 (Reuters) - U.S. health regulators said on Monday they could not definitively link Novartis AG 's multiple sclerosis pill Gilenya with the deaths of people who took the drug.